Vietnam is emerging as one of Southeast Asia's fastest-growing markets for GLP-1 receptor agonists, as rising rates of diabetes and obesity fuel demand for innovative therapies that improve blood glucose control while supporting significant weight loss.
Although a dedicated market valuation for Vietnam has not yet been published, industry analysis estimates the country's GLP-1 receptor agonists market is currently worth US$38–55 million in 2025 and is projected to reach US$95–135 million by 2030.
GLP-1 receptor agonists—including medicines such as Ozempic® (semaglutide), Wegovy®, Victoza® (liraglutide), Trulicity® (dulaglutide) and Mounjaro® (tirzepatide)—have transformed the treatment of type 2 diabetes and obesity. These therapies improve glycaemic control, promote sustained weight loss and have demonstrated cardiovascular and renal benefits in many patients.
The rapid expansion of the market is being driven by several structural trends:
- Increasing prevalence of type 2 diabetes across Vietnam.
- Rising obesity rates in both adults and younger populations.
- Growing awareness of the cardiovascular and metabolic benefits of GLP-1 therapies.
- Expansion of specialist diabetes and endocrinology services.
- Greater availability of innovative injectable therapies through hospitals and private healthcare providers.
- Increasing healthcare expenditure and improved access to advanced medicines.
Vietnam's broader diabetes treatment market provides a strong foundation for future growth. According to IMARC Group, the country's diabetes drugs market reached US$375 million in 2025 and is forecast to grow to US$625.5 million by 2034, with non-insulin injectable therapies—including GLP-1 receptor agonists—representing one of the fastest-growing product categories.
Demand is also being supported by wider changes in healthcare and lifestyle. Vietnam's weight loss market reached US$1.29 billion in 2025 and is projected to exceed US$2.6 billion by 2034, reflecting increasing consumer awareness of obesity management and preventive healthcare. As GLP-1 medicines become more widely available, they are expected to play an increasingly important role in medically supervised weight management programmes.
Globally, GLP-1 therapies are reshaping pharmaceutical markets. IMARC Group estimates the global GLP-1 receptor agonist market reached US$29.0 billion in 2025 and is forecast to grow to US$58.3 billion by 2034, driven by expanding indications beyond diabetes, including obesity, cardiovascular disease and chronic kidney disease.
Leading manufacturers including Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi and emerging biotechnology companies continue to invest heavily in next-generation incretin therapies, including dual- and triple-receptor agonists, oral GLP-1 formulations and combination metabolic treatments. These innovations are expected to further expand treatment options and drive market growth over the coming decade.
As Vietnam continues to modernise diabetes care and address the growing burden of metabolic disease, GLP-1 receptor agonists are expected to become an increasingly important component of treatment pathways. For pharmaceutical manufacturers, contract manufacturing organisations, cold-chain logistics providers, injector device manufacturers and healthcare technology suppliers, Vietnam represents one of Southeast Asia's most promising long-term growth opportunities.